Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials

Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials

Abstract Background Non-small cell lung cancer (NSCLC) with HER2 mutation has entered into the era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) showed moderate objective response rate (ORR) and median progression-free survival (PF...

Full description

Bibliographic Details
Main Authors: Shiqi Mao, Shuo Yang, Xinyu Liu, Xingya Li, Qiming Wang, Yiping Zhang, Jianhua Chen, Yan Wang, Guanghui Gao, Fengying Wu, Tao Jiang, Jiao Zhang, Ying Yang, Xiang Lin, Xiaoyu Zhu, Caicun Zhou, Shengxiang Ren
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Experimental Hematology & Oncology
Subjects:
Non-small cell lung cancer
HER2 mutation
pyrotinib 
ctDNA
Online Access:https://doi.org/10.1186/s40164-023-00417-y

Internet

https://doi.org/10.1186/s40164-023-00417-y

Similar Items